Reflexion Announces Newly Formed Scientific Advisory Board
Dwight E.Heron，M.D.，M.B.A。 Bon Securs Mercy Health System， and director of the Radiosurgery Institute at Mercy St.Elizabeth-Youngstown.He previously held clinical and academic tenures at University of Pittsburgh Medical Center.His research centers on PET/CT for staging and managing cancer，and stereotactic radiosurgery for brain，head and neck，lung， pancreas and liver tumors.He is president-elect of the American College of Radiation Oncology。 Kristin Higgins，M.D。 企业内部通用性， where she specializes in the treatment of thoracic malignancies.Her research work includes clinical trial development including novel radiation therapy and drug combinations.She leads clinical trials within NRG Oncology and is an international expert in the treatment of non-small cellng cancer（NSCLC and sluncell。 Robert D.Timmerman，M.D。 is professor of Radiation Oncology and Neurosurgery，interim chair of Radiation Oncology and Efffie Marie Cain Distinguished Chair in Cancer Therapy Research at the University of Texas Southwestern Medical Center.After treating thousands of patients with brain tumors using highly potent and focused stereactoractoractic，apy， helped pioneer translation of this approach to lung，liver，spine，breast，and prostate tumors as principal or co-investigator on prospective trials evaluating efficacy and toxicity of stereotactive ablative radiotherapy。 Phuoc T.Tran，M.D.，Ph.D。 单击功能区上， is a professor of Radiation Oncology and Molecular Radiation Sciences at Johns Hopkins University.He co-directs the Program in Cancer Invasion and Metastasis and has co-appointments in Medical Oncology， at the James Buchanan Brady Urological Institute and the Cellular and Molecular Medicine Program.His research focues on tumor cell epithelial plasticity and novel agents to enhance the local and systemic effets of radiation。 James Welsh，M.D。 is a tenured professor and physician scientist at MD Anderson Cancer Center and is the director of the Immune Radiation program.His research centers on using radiation to turn the tumor into an“in-situ”vaccine to prime T cells， thus turning radiation into asystemic therapy.He specializes in checkpoint inhibitor resistance and has developed a novel way of using“low”dose radiation to overcome barriers of the tumor stroma to pull immune cells into solid tumors。
John Heymach，M.D.，Ph.D。 is department chair of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center.His laboratory focuses on the mechanisms of therapeutic resistance to targeted agents，the regulation of angiogenesis in lung cancer，and developing biomarkers to select patients likely to benefit from targeted agents and munoy。 Jason Luke，M.D。 is the director of the Cancer Immunotherapeutics Center at University of Pittsburgh Hillman Cancer Center and associate professor of Medicine at the University of Pittsburgh.Dr.Luke is an internationally recognized clinical and translational investigator in cancer drug development，particularly imnomuthery， and has been at the forefront of studying multi-site irradiation in combination with immuno-oncology combination therapies。 Melinda Telli，M.D。 is an associate professor of Medicine in the Division of Medical Oncology at Stanford University School of Medicine and director of the Breast Cancer Program at the Stanford Cancer Institute.Dr.Telli’s research focues on developing novel therapies for the treatment of triple-negative and hereditary breast cancer。
Chaitanya Divgi，M.D。 is a nuclear oncologist with over30years of academic experience including tenures at Memorial Sloan Kettering Cancer Center，the University of Pennsylvania and Columbia University.He is a leader in the assessment of imagin。 Martin Pomper，M.D.，Ph.D。 is the Henry N.Wagner，Jr.M.D.professor，director of the Division of Nuclear Medicine and Molecular Imaging and associate dean for Entrepreneurship and Technology Development at Johns Hopkins Medical School.He is internationally known for developping new radiophaceuticals， including imaging and therapeutic agents targeting the prostate-specific membrane antigen.His research also includes developing new imaging agents for central nervous system disease and other disorders。
